arna-10q_20180630.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to

Commission File Number: 000-31161

 

ARENA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

23-2908305

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

6154 Nancy Ridge Drive, San Diego, CA

 

92121

(Address of principal executive offices)

 

(Zip Code)

 

858.453.7200

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.      Yes      No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes      No  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  (Do not check if a small reporting company)

  

Small reporting company

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes      No

The number of shares of common stock outstanding as of the close of business on August 2, 2018:

 

Class

 

Number of Shares Outstanding

Common Stock, $0.0001 par value

 

49,348,189

 

 

 

 


 

ARENA PHARMACEUTICALS, INC.

INDEX

 

PART I—FINANCIAL INFORMATION

Item 1.

Financial Statements

1

 

Condensed Consolidated Balance Sheets - As of June 30, 2018, and December 31, 2017

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss - Three and Six Months Ended June 30, 2018, and 2017

2

 

Condensed Consolidated Statements of Cash Flows - Six Months Ended June 30, 2018, and 2017

3

 

Notes to Unaudited Condensed Consolidated Financial Statements

4

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

24

Item 4.

Controls and Procedures

24

PART II—OTHER INFORMATION

Item 1.

Legal Proceedings

25

Item 1A.

Risk Factors

27

Item 6.

Exhibits

50

Signatures

51

 

 

TRADEMARKS AND CERTAIN TERMS

Arena Pharmaceuticals ® and Arena ® are registered service marks of Arena. Any other brand names or trademarks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders.

In this Quarterly Report on Form 10-Q, “Arena Pharmaceuticals,” “Arena,” “we,” “us” and “our” refer to Arena Pharmaceuticals, Inc., and our wholly owned subsidiaries on a consolidated basis, unless the context otherwise provides. “APD” is an abbreviation for Arena Pharmaceuticals Development.

 

 

i


 

PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements.

ARENA PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

 

 

June 30,

 

 

December 31,

 

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

501,217

 

 

$

158,837

 

Short-term investments, available-for-sale

 

 

91,190

 

 

 

88,240

 

Accounts receivable

 

 

2,334

 

 

 

2,357

 

Insurance recovery receivable

 

 

 

 

 

12,025

 

Prepaid expenses and other current assets

 

 

6,539

 

 

 

2,681

 

Assets of disposal group held for sale

 

 

 

 

 

17,140

 

Total current assets

 

 

601,280

 

 

 

281,280

 

Investments, available-for-sale

 

 

 

 

 

24,242

 

Land, property and equipment, net

 

 

28,756

 

 

 

30,131

 

Other non-current assets

 

 

7,524

 

 

 

3,622

 

Total assets

 

$

637,560

 

 

$

339,275

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable and other accrued liabilities

 

$

6,855

 

 

$

7,916

 

Accrued clinical and preclinical study fees

 

 

9,668

 

 

 

7,706

 

Accrued litigation settlement

 

 

 

 

 

24,000

 

Current portion of deferred revenues

 

 

800

 

 

 

1,110

 

Current portion of lease financing obligations

 

 

3,594

 

 

 

4,000

 

Liabilities of disposal group held for sale

 

 

 

 

 

27,595

 

Total current liabilities

 

 

20,917

 

 

 

72,327

 

Other long-term liabilities

 

 

1,011

 

 

 

989

 

Deferred revenues, less current portion

 

 

615

 

 

 

1,067

 

Lease financing obligations, less current portion

 

 

56,179

 

 

 

57,748

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

5

 

 

 

4

 

Additional paid-in capital

 

 

2,093,958

 

 

 

1,698,543

 

Accumulated other comprehensive loss

 

 

(177

)

 

 

(1,216

)

Accumulated deficit

 

 

(1,534,948

)

 

 

(1,490,187

)

Total stockholders' equity

 

 

558,838

 

 

 

207,144

 

Total liabilities and stockholders' equity

 

$

637,560

 

 

$

339,275

 

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

1


 

ARENA PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

Six months ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration and other revenue

 

$

3,133

 

 

$

1,898

 

 

$

4,161

 

 

$

3,558

 

Royalty revenue

 

 

861

 

 

 

 

 

 

1,588

 

 

 

 

Total revenues

 

 

3,994

 

 

 

1,898

 

 

 

5,749

 

 

 

3,558

 

Operating Costs and Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

26,755

 

 

 

17,700

 

 

 

48,328

 

 

 

33,044

 

General and administrative

 

 

10,405

 

 

 

7,150

 

 

 

21,556

 

 

 

14,670

 

Total operating costs and expenses

 

 

37,160

 

 

 

24,850

 

 

 

69,884

 

 

 

47,714

 

Loss from operations

 

 

(33,166

)

 

 

(22,952

)

 

 

(64,135

)

 

 

(44,156

)

Interest and Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

2,502

 

 

 

16

 

 

 

3,276

 

 

 

50

 

Interest expense

 

 

(1,448

)

 

 

(1,538

)

 

 

(2,920

)

 

 

(3,108

)

Other income

 

 

279

 

 

 

711

 

 

 

813

 

 

 

900

 

Total interest and other income (expense), net

 

 

1,333

 

 

 

(811

)

 

 

1,169

 

 

 

(2,158

)

Loss from continuing operations

 

 

(31,833

)

 

 

(23,763

)

 

 

(62,966

)

 

 

(46,314

)

Income (loss) from discontinued operations

 

 

 

 

 

147

 

 

 

(830

)

 

 

201

 

Net loss

 

 

(31,833

)

 

 

(23,616

)

 

 

(63,796

)

 

 

(46,113

)

Less net loss attributable to noncontrolling interest in

   consolidated variable interest entity

 

 

 

 

 

299

 

 

 

 

 

 

743

 

Net loss attributable to stockholders of Arena

 

$

(31,833

)

 

$

(23,317

)

 

$

(63,796

)

 

$

(45,370

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amounts attributable to stockholders of Arena:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from continuing operations

 

$

(31,833

)

 

$

(23,464

)

 

$

(62,966

)

 

$

(45,571

)

Income (loss) from discontinued operations

 

 

 

 

 

147

 

 

 

(830

)

 

 

201

 

 

 

$

(31,833

)

 

$

(23,317

)

 

$

(63,796

)

 

$

(45,370

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to stockholders of Arena per

     share, basic and diluted:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.65

)

 

$

(0.77

)

 

$

(1.41

)

 

$

(1.66

)

Discontinued operations

 

 

 

 

 

 

 

 

(0.02

)

 

 

 

 

 

$

(0.65

)

 

$

(0.77

)

 

$

(1.43

)

 

$

(1.66

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in calculating net income (loss) attributable to

     stockholders of Arena per share, basic and diluted:

 

 

49,263

 

 

 

30,299

 

 

 

44,655

 

 

 

27,371

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive Loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(31,833

)

 

$

(23,616

)

 

$

(63,796

)

 

$

(46,113

)

Foreign currency translation gain (loss)

 

 

(50

)

 

 

1,910

 

 

 

(33

)

 

 

2,714

 

Unrealized gain (loss) on available-for-sale investments

 

 

113

 

 

 

 

 

 

(31

)

 

 

 

Comprehensive loss

 

 

(31,770

)

 

 

(21,706

)

 

 

(63,860

)

 

 

(43,399

)

Less comprehensive loss attributable to noncontrolling interest

    in consolidated variable interest entity

 

 

 

 

 

299

 

 

 

 

 

 

743

 

Comprehensive loss attributable to stockholders of Arena

 

$

(31,770

)

 

$

(21,407

)

 

$

(63,860

)

 

$

(42,656

)

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

2


 

ARENA PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2018

 

 

2017

 

Operating Activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(63,796

)

 

$

(46,113

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

(Income) loss from discontinued operations

 

 

830

 

 

 

(201

)

Depreciation and amortization

 

 

1,902

 

 

 

2,190

 

Non-cash collaboration consideration

 

 

(1,500

)

 

 

 

Share-based compensation

 

 

8,563

 

 

 

3,881

 

Amortization of prepaid financing costs

 

 

55

 

 

 

68

 

Amortization of original issue discounts, net of premiums, on available-for-sale

      investments

 

 

(162

)

 

 

 

Gain on disposal of property and equipment

 

 

 

 

 

(393

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

165

 

 

 

11,974

 

Prepaid expenses and other assets

 

 

(635

)

 

 

(921

)

Payables and accrued liabilities

 

 

349

 

 

 

(5,623

)

Accrued litigation settlement

 

 

(11,975

)

 

 

 

Deferred revenues

 

 

(646

)

 

 

(2,190

)

Other long-term liabilities

 

 

(551

)

 

 

(28

)

Net cash used in operating activities - continuing operations

 

 

(67,401

)

 

 

(37,356

)

Net cash used in operating activities - discontinued operations

 

 

(102

)

 

 

(4,829

)

Net cash used in operating activities

 

 

(67,503

)

 

 

(42,185

)

Investing Activities:

 

 

 

 

 

 

 

 

Purchases of available-for-sale investments

 

 

(25,477

)

 

 

 

Proceeds from sale and maturity of available-for-sale investments

 

 

46,900

 

 

 

 

Purchases of property and equipment

 

 

(528

)

 

 

(25

)

Other non-current assets

 

 

2

 

 

 

(6

)

Net cash used in investing activities - continuing operations

 

 

20,897

 

 

 

(31

)

Net cash provided by investing activities - discontinued operations

 

 

3,405

 

 

 

31

 

Net cash provided by investing activities

 

 

24,302

 

 

 

 

Financing Activities:

 

 

 

 

 

 

 

 

Principal payments on lease financing obligations

 

 

(1,976

)

 

 

(1,684

)

Proceeds from issuance of common stock, net

 

 

387,009

 

 

 

81,496

 

Net cash provided by financing activities

 

 

385,033

 

 

 

79,812

 

Effect of exchange rate changes on cash

 

 

548

 

 

 

2,424

 

Net increase in cash, cash equivalents and restricted cash

 

 

342,380

 

 

 

40,051

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

159,700

 

 

 

91,575

 

Cash, cash equivalents and restricted cash at end of period

 

$

502,080

 

 

$

131,626

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 

3


 

ARENA PHARMACEUTICALS, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

 

 

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Arena Pharmaceuticals, Inc. should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission, or SEC, from which we derived our condensed consolidated balance sheet as of December 31, 2017. The accompanying condensed consolidated financial statements have been prepared in accordance with US generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Beacon Discovery, Inc., or Beacon, is a variable interest entity in which we had a controlling financial interest until December 2017. The results of operations and comprehensive loss attributable to the noncontrolling interest in Beacon are presented as separate components from the results of operations and comprehensive loss attributable to the stockholders of Arena in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2017. We deconsolidated Beacon in December 2017 (see Note 13).

Liquidity.

As of June 30, 2018, we had cash, cash equivalents and available-for-sale investments of approximately $592.4 million. We believe our cash and cash equivalents and available-for-sale investments will be sufficient to fund our operations for at least the next 12 months.

We will require substantial cash to achieve our objectives of discovering, developing and commercializing drugs, as this process typically takes many years and potentially hundreds of millions of dollars for an individual drug. We may not have adequate available cash, or assets that could be readily turned into cash, to meet these objectives in the long term. We will need to obtain significant funds under our existing collaborations, under new collaboration, licensing or other commercial agreements for one or more of our drug candidates, programs or patent portfolios, or from other potential sources of liquidity, which may include the sale of equity, issuance of debt or other transactions.

Changes in Accounting Policies - Revenue Recognition.

Effective January 1, 2018, we adopted Accounting Standard Codification 606, Revenue from Contracts with Customers, or ASC 606, issued by the Financial Accounting Standards Board, or FASB. As a result, we have changed our accounting policy for revenue recognition as detailed below.

We implemented ASC 606 using the modified retrospective method by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of our accumulated deficit at January 1, 2018. Therefore, the comparative period information has not been adjusted.

We applied ASC 606 using a practical expedient for contracts that were modified before the implementation date, which allowed us to determine an aggregate effect of all modifications that occurred before January 1, 2018, when determining the satisfied and unsatisfied performance obligations, the transaction price, and allocating that transaction price to the performance obligations instead of retrospectively restating the contracts for such contract modifications.  

The cumulative impact to our accumulated deficit balance at January 1, 2018, as a result of the adoption of ASC 606 was a decrease of $19.0 million. The decrease arose primarily from a reduction of deferred revenue balances related to upfront payments received from customers and recognition of contract assets due to a combination of (i) the effects of applying the practical expedient for contract modifications and our conclusions related to satisfied and unsatisfied performance obligations, which resulted in a relatively higher portion of the total transaction price recognized as revenue in periods prior to our adoption of ASC 606, (ii) the effect of the bill-and-hold accounting guidance for inventory in ASC 606 and (iii) the inclusion of estimated future royalty payments related to our intellectual property in the total transaction price to the extent such intellectual property was legally sold to our customer rather than licensed. The cumulative effect adjustment is net of an impairment loss of $13.1 million which was a direct effect of the adoption

4


 

of ASC 606 on the asset group of the Manufacturing Operations, which was classified as assets of disposal group held for sale since December 2017.

The following table summarizes the impacts of adopting ASC 606 on our condensed consolidated financial statements, in thousands.

 

 

 

Impact of Changes in Accounting Policies

 

Three months ended June 30, 2018

 

As reported

 

 

Adjustments

 

 

Balances without adoption of ASC 606

 

Collaboration and other revenue

 

$

3,133

 

 

$

(15

)

 

$

3,118

 

Royalty revenue

 

 

861

 

 

 

426

 

 

 

1,287

 

Total revenue

 

 

3,994

 

 

 

411

 

 

 

4,405

 

Loss from operations

 

 

(33,166

)

 

 

411

 

 

 

(32,755

)

Loss from continuing operations

 

 

(31,833

)

 

 

411

 

 

 

(31,422

)

Net loss

 

 

(31,833

)

 

 

411

 

 

 

(31,422

)

Net loss attributable to stockholders of Arena

 

 

(31,833

)

 

 

411

 

 

 

(31,422

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Six months ended June 30, 2018

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration and other revenue

 

$

4,161

 

 

$

44

 

 

$

4,205

 

Royalty revenue

 

 

1,588

 

 

 

688

 

 

 

2,276

 

Total revenue

 

 

5,749

 

 

 

732

 

 

 

6,481

 

Loss from operations

 

 

(64,135

)

 

 

732

 

 

 

(63,403

)

Loss from continuing operations

 

 

(62,966

)

 

 

1,880

 

 

 

(61,086

)

Income (loss) from discontinued operations

 

 

(830

)

 

 

13,660

 

 

 

12,830

 

Net loss

 

 

(63,796

)

 

 

15,540

 

 

 

(48,256

)

Net loss attributable to stockholders of Arena

 

 

(63,796

)

 

 

15,540

 

 

 

(48,256

)

 

 

 

 

 

 

 

 

 

 

 

 

 

As of June 30, 2018

 

 

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

$

6,539

 

 

$

(1,059

)

 

$

5,480

 

Total current assets

 

 

601,280

 

 

 

(1,059

)

 

 

600,221

 

Other non-current assets

 

 

7,524

 

 

 

(2,361

)

 

 

5,163

 

Total assets

 

 

637,560

 

 

 

(3,420

)

 

 

634,140

 

Current portion of deferred revenues

 

 

800

 

 

 

20

 

 

 

820

 

Total current liabilities

 

 

20,917

 

 

 

20

 

 

 

20,937

 

Deferred revenues, less current portion

 

 

615

 

 

 

52

 

 

 

667

 

Accumulated deficit

 

 

(1,534,948

)

 

 

(3,492

)

 

 

(1,538,440

)

Total stockholders' equity

 

 

558,838

 

 

 

(3,492

)

 

 

555,346

 

Total liabilities and stockholders' equity

 

 

637,560

 

 

 

(3,420

)

 

 

634,140

 

 

Our revenues to date have been generated primarily through collaboration agreements. Our collaboration agreements frequently contain multiple elements including (i) intellectual property licenses, (ii) product research, development and regulatory services and (iii) product manufacturing. Consideration we receive under these arrangements may include upfront payments, research and development funding, cost reimbursements, milestone payments, payments for product sales and royalty payments. Our customers include Everest Medicines Limited, or Everest, Outpost Medicine, LLC, or Outpost, Eisai Inc. and Eisai Co., Ltd., or collectively, Eisai, Axovant Sciences GmbH, or Axovant, Boehringer Ingelheim International GmbH, or Boehringer Ingelheim, and Siegfried.  

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that we expect to be entitled to receive in exchange for these services and excludes sales incentives and amounts collected on behalf of third parties. We analyze the nature of these performance obligations in the context of individual collaboration agreements in order to assess the distinct performance obligations. We apply the following five steps to recognize revenue:

i) Identify the contract with a customer. We consider the terms and conditions of our collaboration agreements to identify contracts within the scope of ASC 606. We consider that we have a contract with a customer when the contract is approved, we can identify each party's rights regarding the goods and services to be transferred, we can identify the payment terms for the goods and services, we have determined the customer has the ability and intent to pay and the contract has commercial substance. We use

5


 

judgment in determining the customer's ability and intent to pay, which is based upon factors including the customer's historical payment experience or, for new customers, credit and financial information pertaining to the customers.

ii) Identify the performance obligations in the contract. Performance obligations in our collaboration agreements are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. Our performance obligations generally consist of intellectual property licenses, research, development and/or regulatory services and manufacturing and supply commitments.

 iii) Determine the transaction price. We determine the transaction price based on the consideration to which we expect to be entitled in exchange for transferring goods and services to the customer. In determining the transaction price, any variable consideration would be considered, to the extent applicable, if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. In accordance with the royalty exception under ASC 606 for licenses of intellectual property, the transaction price excludes future royalty payments to be received from our customers. None of our collaboration agreements contain consideration payable to our customer or a significant financing component.

 iv) Allocate the transaction price to performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to that performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative standalone selling price.

 v) Recognize revenue when or as we satisfy a performance obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised goods or services to a customer. We recognize revenue when we transfer control of the goods or services to our customers for an amount that reflects the consideration that we expect to receive in exchange for those services.

Performance Obligations.

The following is a description of principal goods and services from which we generate revenue.

 

Intellectual property licenses

We generate revenue from licensing our intellectual property including know-how and development and commercialization rights. These licenses provide customers with a term-based license to further research, develop and commercialize our internally-discovered drug candidates. The consideration we receive in the form of nonrefundable upfront consideration related to the functional intellectual property licenses is recognized when we transfer such license to the customer unless the license is combined with other goods or services into one performance obligation, in which case the revenue is recognized over a period of time based on our estimated pattern in which we satisfy the combined performance obligation. Our licensing agreements are generally cancelable. Customers have the right to terminate their contracts upon notice. We have the right to terminate the contracts generally only if the customer is in breach of the contract and fails to remedy the breach in accordance with the contractual terms.

 

Intellectual property sales

We generate royalty revenue from sales of our intellectual property. We estimate the future royalty payments and recognize revenue with a corresponding contract asset at a point in time when we transfer the intellectual property to the customer.

 

Research, development and regulatory services

We generate revenue from research, development and regulatory services we provide to our customers in connection with the licensed intellectual property. The services we provide to our customers primarily include scientific research activities, preparation for and management of clinical trials, and assistance during the regulatory approval application process. Revenue associated with these services is recognized based on our estimate of total consideration to be received for such services and the pattern in which we perform the services. The pattern of performance is generally determined to be the amount of incurred expenses reimbursed by the customer as a percentage of total expected reimbursable expenses associated with the contract.

 

Product manufacturing

We generate revenue from manufacturing and clinical supply promises to our customers in connection with securing a supply of drug products for development and clinical trial purposes. The drug products are generally manufactured by our contract manufacturing organizations. We used our product manufacturing facility in Zofingen, Switzerland for a portion of the product

6


 

manufacturing requirements until we sold the Manufacturing Operations on March 31, 2018 (see Note 2). Revenue associated with product manufacturing obligations is recognized at a point in time as control of the related product is transferred to the customer.

Contracts with Multiple Performance Obligations.

Most of our collaboration agreements with customers contain multiple promised goods or services. Based on the characteristics of the promised goods and services we analyze whether they are separate or combined performance obligations. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price based on our overall pricing and discounting objectives, taking into consideration the type of services, estimates of hourly market rates, and stage of the development and clinical trials.

Variable Consideration.

Our contracts with customers primarily include two types of variable consideration: (i) development and regulatory milestone payments, which are due to us upon achievement of specific development and regulatory milestones and (ii) one-time sales-based payments and sales-based royalties associated with sold or licensed intellectual property.

Due to uncertainty associated with achievement of the development and regulatory milestones, the related milestone payments are excluded from the contract consideration and the corresponding revenue is not recognized until we conclude it is probable that reversal of such milestone revenue will not occur.

Product sales-based royalties under licensed intellectual property and one-time payments are accounted for under the royalty exception. We recognize revenue for sales-based royalties under licensed intellectual property and one-time payments at the later of when the sales occur or the performance obligation is satisfied or partially satisfied.

Disaggregation of Revenue.

We operate in one reportable business segment. We provide goods and services to our customers in collaboration agreements pursuant to various geographical markets. In the following table, revenue is disaggregated by major customers, timing of revenue recognition and revenue classification, in thousands.

 

Customers

 

Three months ended June 30, 2018

 

 

Six months ended     June 30, 2018

 

Outpost

 

$

2,750

 

 

$

2,750

 

Eisai

 

 

861

 

 

 

3,089

 

Siegfried

 

 

 

 

 

942

 

Axovant

 

 

200

 

 

 

768

 

Boehringer Ingelheim

 

 

163

 

 

 

623

 

Other

 

 

20

 

 

 

84

 

    Total

 

$

3,994

 

 

$

8,256

 

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

 

Goods and services transferred at a point in time

 

$

2,770

 

 

$

5,277

 

Goods and services transferred over time

 

 

1,224

 

 

 

2,979

 

    Total

 

$

3,994

 

 

$

8,256

 

 

 

 

 

 

 

 

 

 

Classification

 

 

 

 

 

 

 

 

Revenue from continuing operations

 

$

3,994

 

 

$

5,749

 

Revenue reported under discontinued operations

 

 

 

 

 

2,507

 

    Total

 

$

3,994

 

 

$

8,256

 

 

Contract Assets and Contract Liabilities.

We receive payments from customers based on contractual terms. Accounts receivable are recorded when the right to consideration becomes unconditional. For research and development services, we generally bill our customers monthly or quarterly as the services are performed. Product sales are generally billed as completed. Payment terms on invoiced amounts are typically 30 days. Contract assets include amounts related to our contractual right to consideration for both completed and partially completed performance obligations that have not been invoiced. The current portion of contract assets is included in prepaid expenses and other

7


 

current assets in the condensed consolidated balance sheet. The non-current portion of contract assets is included in other non-current assets in the condensed consolidated balance sheet. As of January 1, 2018, we recorded a contract asset of $4.1 million, of which $1.4 million is classified as current and $2.7 million is classified as non-current, related to future royalties associated with intellectual property patents previously sold to a customer which do not qualify for the royalty exception in ASC 606. We estimated the amount of the contract asset by applying the expected value method to our estimate of future royalty payments we will receive from this customer. Any future changes to this estimate will be recorded as an adjustment to revenue in the period in which the change in estimate is made.  

Contract liabilities consist of deferred revenue and include payments received in advance of performance under the contract.

The following table provides detail of changes in our contract assets and deferred revenues, in thousands. The deferred revenue balances as of December 31, 2017, presented in the following table include balances classified as liabilities of disposal group held for sale:

 

 

 

Contract Assets

- Current

 

 

Contract Assets -

Non-Current

 

 

Current Portion of Deferred Revenues

 

 

Deferred Revenues, Less Current Portion

 

Balances at December 31, 2017

 

$

 

 

$

 

 

$

26,560

 

 

$

1,067

 

ASC 606 implementation adjustments

 

 

7,527

 

 

 

2,694

 

 

 

(25,526

)

 

 

(40

)

Reductions of contract assets

 

 

(2,070

)

 

 

(333

)

 

 

 

 

 

 

Impact of the disposal of the Manufacturing

     Operations (see Note 2)

 

 

(4,543

)

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

145

 

 

 

 

 

 

 

 

 

 

Recognized as revenue during the period

 

 

 

 

 

 

 

 

(234

)

 

 

(412

)

Balances at June 30, 2018

 

$

1,059

 

 

$

2,361

 

 

$

800

 

 

$

615

 

Cost to Obtain and Fulfill a Contract.

We generally do not incur costs to obtain new contracts. Costs to fulfill contracts are expensed as incurred.

Remaining Performance Obligations.

The following table provides detail of estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to our existing collaboration agreements as of June 30, 2018, in thousands:

 

 

 

As of June 30, 2018

 

Rest of 2018

 

$

1,332

 

2019

 

 

2,069

 

2020

 

 

672

 

2021 and thereafter

 

 

 

    Total

 

$

4,073

 

Under the royalty exception in ASC 606 for licensed intellectual property we do not recognize any revenue for the variable amounts related to sales-based royalties until the later of when the sales occur or the performance obligation is satisfied or partially satisfied. Accordingly, the revenue related to future royalties and sales-based milestones is not included in the table above.

Recent Accounting Pronouncements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU No. 2016-02 amends the accounting guidance for leases. The amendments contain principles that will require lessees to recognize most leases on the balance sheet by recording a right-of-use asset and a lease liability, unless the lease is a short-term lease that has an accounting lease term of 12 months or less. The amendments also contain other changes to the current lease guidance that may result in changes to how entities determine which contractual arrangements qualify as a lease, the accounting for executory costs (such as property taxes and insurance), as well as which lease origination costs will be capitalizable. The new standard also requires expanded quantitative and qualitative disclosures. The FASB has subsequently issued additional ASUs to clarify certain elements of the new lease accounting guidance. ASU No. 2016-02 is effective for annual reporting periods, and interim periods within those periods, beginning after December 15, 2018, with early adoption permitted. ASU No. 2016-02 requires the use of the modified retrospective transition method, whereby the new guidance

8


 

will be applied at the beginning of the earliest period presented in the financial statements of the period of adoption. We are currently evaluating the impact of ASU No. 2016-02 on our consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash. ASU No. 2016-18 requires that restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. In accordance with ASU No. 2016-18, we adopted this standard in the first quarter of 2018 and retrospectively adjusted the condensed consolidated statement of cash flows for the six months ended June 30, 2017, to conform to the current period’s presentation. The adoption of this ASU did not have a material impact on our consolidated financial statements.  

The following table provides a reconciliation of the components of cash, cash equivalents, and restricted cash reported in our condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows, in thousands:

 

 

 

June 30,

 

 

December 31,

 

 

 

2018

 

 

2017

 

Cash and cash equivalents

 

$

501,217

 

 

$

158,837

 

Restricted cash included in other non-current assets

 

 

863

 

 

 

863

 

Total cash, cash equivalents and restricted cash presented in the condensed

     consolidated statement of cash flows

 

$

502,080

 

 

$

159,700

 

The restricted cash relates to our property leases. The restriction will lapse when the related leases expire.

Use of Estimates.

The preparation of financial statements in accordance with GAAP requires our management to make estimates and assumptions that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. The amounts reported could differ under different estimates and assumptions.

Contingencies.

We disclose information regarding each material claim where the likelihood of a loss contingency is probable or reasonably possible. If a loss contingency is probable and the amount of the loss can be reasonably estimated, we record an accrual for the loss. In such cases, there may be an exposure to potential loss in excess of the amount accrued. The insurance recoveries are recorded in the period when the insurance reimbursement is deemed probable. The ability to predict the ultimate outcome of such matters involves judgments, estimates and inherent uncertainties. The actual outcome of such matters could differ materially from management’s estimates. 

 

 

2. Sale of Manufacturing Operations

In order to further focus our efforts and resources on our strategic objectives of developing our pipeline drug candidates, on March 9, 2018, we entered into an Asset Purchase Agreement, or Sale Agreement, with Siegfried Pharma AG and Siegfried AG, (collectively and individually, Siegfried). Under the Sale Agreement, we agreed to sell and assign to Siegfried, and Siegfried agreed to purchase and assume from Arena GmbH, certain drug product finishing facility assets and know-how, including fixtures, equipment, other personal property and real estate assets located in Zofingen, Switzerland and related contracts and certain related liabilities, or collectively, the Manufacturing Operations. We refer to this transaction as the Siegfried Transaction. The Siegfried Transaction was completed on March 31, 2018. In connection with the Siegfried Transaction, all of Arena GmbH’s approximately 50 employees transferred to Siegfried. We have excluded from our continuing operations for all periods presented in this report revenues and expenses associated with the disposed Manufacturing Operations, which are reported as discontinued operations. The total sales price for the Manufacturing Operations was approximately CHF 4 million of which approximately CHF 3 million was received in cash in March 2018 with the remaining portion to be received in March 2019, net of any qualifying claims by Siegfried. In the event Siegfried agrees to sell or transfer some or all of the transferred assets to certain third parties on or prior to December 31, 2018, for a consideration in excess of a specified amount, Arena GmbH will be entitled to percentage of such excess amount.

We have retrospectively revised the condensed consolidated statements of operations for the three and six months ended June 30, 2017, and cash flows for the six months ended June 30, 2017, to reflect the operations and cash flows of the disposed Manufacturing Operations as discontinued operations. The following table summarizes the results of discontinued operations for the periods presented in the condensed consolidated statements of operations, in thousands:

9


 

 

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

Revenues

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Net product sales

 

$

 

 

$

2,059

 

 

$

1,129

 

 

$

4,770

 

Other collaboration revenue

 

 

 

 

 

1,781

 

 

 

372

 

 

 

3,316

 

Toll manufacturing

 

 

 

 

 

754

 

 

 

1,006

 

 

 

1,472

 

Total revenues

 

 

 

 

 

4,594

 

 

 

2,507

 

 

 

9,558

 

Costs and expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales

 

 

 

 

 

1,497

 

 

 

1,858

 

 

 

4,029

 

Cost of toll manufacturing

 

 

 

 

 

1,074

 

 

 

1,411

 

 

 

1,993

 

Research and development

 

 

 

 

 

222

 

 

 

 

 

 

389

 

General and administrative

 

 

 

 

 

86

 

 

 

329

 

 

 

730

 

Other expenses, net

 

 

 

 

 

1,568

 

 

 

464

 

 

 

2,216

 

Total costs and expenses

 

 

 

 

 

4,447

 

 

 

4,062

 

 

 

9,357

 

Income (loss) from operations of discontinued operations

 

 

 

 

 

147

 

 

 

(1,555

)

 

 

201

 

Gain on sale of discontinued operations

 

 

 

 

 

 

 

 

725

 

 

 

 

Income (loss) from discontinued operations

 

$

 

 

$

147

 

 

$

(830

)

 

$

201

 

 

 

3. Fair Value Disclosures

We measure our financial assets and liabilities at fair value, which is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

We use the following three-level valuation hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value our financial assets and liabilities:

 

Level 1

 

-

 

Observable inputs such as unadjusted quoted prices in active markets for identical instruments.

 

 

 

 

 

Level 2

 

-

 

Quoted prices for similar instruments in active markets or inputs that are observable for the asset or liability, either directly or indirectly.

 

 

 

 

Level 3

 

-

 

Significant unobservable inputs based on our assumptions.

 

The following tables present our valuation hierarchy for our financial assets and liabilities that are measured at fair value on a recurring basis, in thousands:

 

 

 

Fair Value Measurements at June 30, 2018

 

 

 

Balance

 

 

Quoted Prices in

Active Markets

(Level 1)

 

 

Significant Other

Observable

Inputs

<